Laryngeal Nerve Block for Chronic Cough
Prospective, Single-Blind Randomized Trial of in Office Superior Laryngeal Nerve Block for the Treatment of Chronic Neurogenic Cough
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Recruiting
- Eastern Virginia Medical School Ear, Nose, and Throat Surgeons
-
Sub-Investigator:
- Michael Larson, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years and older
- Previously or Newly Diagnosed Chronic Neurogenic Cough
Exclusion Criteria:
- History of Laryngeal Surgery or External Beam Radiation
- Current Smokers
- Known Allergy or Sensitivity to Local Anesthetics
- Uncontrolled Pulmonary, SinoNasal, or GastroIntestinal Pathology leading to Refractory Chronic Cough
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention (Steroid/Anesthetic Mixture)
The steroid/anesthetic mixture will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
|
Steroid will be Triamcinolone Acetonide (40mg/mL).
Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine.
These will be pre-mixed by a qualified personnel within the ENT department.
|
|
PLACEBO_COMPARATOR: Placebo (Normal Saline)
The placebo (Normal Saline) will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
|
2 mL of Normal Saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention vs. Placebo in Neurogenic Cough using Capsaicin Challenge
Time Frame: Comparing Changes at Pretreatment, at 30 minutes post treatment, at 1 week post treatment, and at 6 weeks post treatment
|
Objectively evaluate the efficacy of blockade of the internal branch of the superior laryngeal nerve with local anesthetic/steroid mixture compared to normal saline placebo in treating chronic neurogenic cough using capsaicin challenge testing to measure cough sensitivity and urge to cough
|
Comparing Changes at Pretreatment, at 30 minutes post treatment, at 1 week post treatment, and at 6 weeks post treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention vs. Placebo in Neurogenic Cough using the Newcastle Laryngeal Hypersensitivity Questionnaire
Time Frame: Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
Subjectively evaluate the efficacy of superior laryngeal nerve block (intervention) vs. placebo using the Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ).
This Questionnaire is scaled from 1 to 7. 1 indicates All of the Time while 7 reflects None of the Time.
|
Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
|
Intervention vs. Placebo in Neurogenic Cough using the Urge to Cough Scale
Time Frame: Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
Subjectively evaluate the efficacy of superior laryngeal nerve block (intervention) vs. placebo using the Urge to Cough Scale.
Higher score indicates more urge, while lower score reflects less of an urge to cough.
|
Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
|
Intervention vs. Placebo in Neurogenic Cough using the Central Sensitization Inventory
Time Frame: Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
Subjectively evaluate the efficacy of superior laryngeal nerve block (intervention) vs. placebo using the Central Sensitization Inventory (CSI).
Scale is ranked as Never, Rarely, Sometimes, Often, and Always and has various symptoms listed.
|
Pretreatment, 30 minutes post treatment, 1 week post treatment, 6 weeks post treatment
|
|
Quality of Life Measurements
Time Frame: Pretreatment, 1 week post treatment, 6 weeks post treatment
|
Analyze quality of life measurements of patients undergoing superior laryngeal nerve block compared to placebo as measured by the Leicester Cough Questionnaire (LCQ).
Scale is from a 1 to 7. The higher the score/rating represents less of a problem while a lower score/rating represents more of a problem.
|
Pretreatment, 1 week post treatment, 6 weeks post treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14Jul2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.